Since intraaortic balloon counterpulsation was utilized for a median of only 3 days, it seems unlikely that any helpful effect will become evident later than thirty days. Nevertheless, additional assessments are prepared at six months and at 12 months for further corroboration of the 30-day findings. In conclusion, we conducted a randomized, controlled trial of intraaortic balloon pump support in patients with cardiogenic shock complicating myocardial infarction for whom early revascularization was planned. Usage of intraaortic balloon counterpulsation, as compared with conventional therapy, didn’t reduce 30-time mortality.. Holger Thiele, M.D., Uwe Zeymer, M.D., Franz-Josef Neumann, M.D., Miroslaw Ferenc, M.D., Hans-Georg Olbrich, M.D.D., Gert Richardt, M.D., Marcus Hennersdorf, M.D., Klaus Empen, M.D., Georg Fuernau, M.D., Steffen Desch, M.D., Ingo Eitel, M.D., Rainer Hambrecht, M.D.D.D., Henning Ebelt, M.D., Steffen Schneider, Ph.D., Gerhard Schuler, M.D., and Karl Werdan, M.D.ArpegioHealth’s team has experience in meeting the requirements of vulnerable populations and will be a huge asset to our member plans, said Margaret A. Murray, chief executive officer of ACAP. We are very happy to welcome them into our organization and also have them as a preferred vendor. ArpegioHealth works with senior leaders to build up integrated solutions to solve complex problems related to growth and switch. ArpegioHealth has a history of successfully helping nationwide clients achieve sustainable outcomes and higher levels of performance. There are various new opportunities coming for ACAP associates to explore, said Dr. Carol J. Geffner, CEO of ArpegioHealth.